GlassScriptPhysician profile
Lubna Mirza
NPI 1326208513
$12,223.48
in general payments reported to CMS, 2019-2025
57 companies · $2,647 in 2025
The $2,647 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,894 · 2020: $770 · 2021: $722 · 2022: $1,032 · 2023: $967 · 2024: $2,192 · 2025: $2,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,824 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $950 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,823.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $950.00 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $2,469.63 | 2019 | |
| Tandem Diabetes Care, INC. | $1,216.51 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $972.80 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $807.62 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $734.62 | 2019-2023 | Farxiga |
| Amgen INC. | $581.04 | 2019-2025 | Evenity, Tepezza, Prolia |
| Sanofi-Aventis U.S. LLC | $536.88 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $469.02 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $382.32 | 2019-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $330.62 | 2019-2020 | |
| Insulet Corporation | $292.03 | 2021-2025 | Omnipod |
| Abbvie INC. | $268.94 | 2019-2024 | |
| Abbott Laboratories | $226.09 | 2019-2025 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $161.37 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $153.13 | 2020-2025 | Isturisa |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $147.66 | 2021-2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.72 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $128.90 | 2022-2025 | |
| Dexcom, INC. | $125.89 | 2021-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $124.67 | 2021 | |
| Merck Sharp & Dohme LLC | $124.53 | 2019-2023 | Verquvo, Steglujan, Steglatro |
| Medtronic, INC. | $124.02 | 2024-2025 | Intellis Adaptivestim, Inceptiv, Minimed 780g |
| Ibsa Pharma INC. | $121.04 | 2019-2023 | Tirosint, Licart |
| Beta Bionics, INC. | $118.24 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $117.95 | 2019-2021 | |
| Mannkind Corporation | $111.22 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $102.66 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $102.53 | 2020-2025 | Strensiq |
| Radius Health, INC. | $94.58 | 2023-2025 | Tymlos |
| Chiesi USA, INC. | $91.98 | 2024-2025 | Mycapssa |
| Cequr Corporation | $87.04 | 2022-2025 | Cequr Simplicity |
| Ultragenyx Pharmaceutical INC. | $84.45 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $77.17 | 2025 | |
| Amarin Pharma, INC. | $67.56 | 2019-2020 | |
| Lifescan, INC. | $49.86 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $47.66 | 2019-2020 | |
| Baxter Healthcare | $44.50 | 2025 | Perclot |
| Amneal Pharmaceuticals LLC | $42.79 | 2023-2025 | Unithroid |
| Echosens North America, INC. | $40.57 | 2024-2025 | Fibroscan, Fibroscan |
| Currax Pharmaceuticals LLC | $39.42 | 2021-2023 | Contrave, Onzetra Xsail |
| Ascensia Diabetes Care US INC. | $34.25 | 2024 | |
| Nevro Corp. | $23.64 | 2024 | Senza |
| Amryt Pharma Holdings LTD | $22.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.61 | 2024 | |
| Sequel Med Tech, LLC | $21.46 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $20.76 | 2025 | Imcivree |
| Glaxosmithkline, LLC. | $20.75 | 2025 | Shingrix |
| Eisai INC. | $19.57 | 2019 | |
| Gilead Sciences, INC. | $19.07 | 2019 | |
| Boston Scientific Corporation | $15.68 | 2025 | Cre Pro |
| Medtronic Minimed, INC. | $13.78 | 2020 | |
| Becton, Dickinson and Company | $13.30 | 2020 | |
| Shire North American Group INC | $12.51 | 2019 | |
| Valeritas, INC. | $11.98 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lubna Mirza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.